Some images has been designed using resources from Unsplash & Pixabay & Pexels & Freepik and some icons from Flaticon
跳到主要內容
Search
:::

洪逸平 (Yi-Ping Hung)

洪逸平(Yi-Ping Hung)圖 Return Appointment First Appointment

[Profile]

  • Education
    • 博士, 臨床醫學研究所; 國立陽明大學, 臺北市,
    • 醫學士, 醫學系; 國立臺灣大學, 臺北市,
  • Career and Experience
    Current Positions：
    • - Now, 主治醫師, 腫瘤醫學部 腫瘤內科, 臺北榮民總醫院, 臺北市,
    • 2021- Now, 助理教授, 醫學院, 國立陽明大學, 臺北市,
    • 2021- Now, 審查委員, 人體試驗委員會, 臺北榮民總醫院, 臺北市,
    • 2021- Now, 副執行秘書, 臨床研究受試者保護中心, 臺北榮民總醫院, 臺北市,
    Experiences：
    • - , 選送博士創新之星LEAP計畫, 科技部,
    • - , 訪問學者, 化工系及癌症中心, 美國史丹佛大學,
    • - , 講師, 醫學系 內科學科, 國立陽明大學, 臺北市,
    • - , 住院總醫師, 內科部 腫瘤科, 臺北榮民總醫院, 臺北市,
    • - , 總醫師, 內科部 血液科, 臺北榮民總醫院, 臺北市,
    • - , 住院醫師, 內科部, 臺北榮民總醫院, 臺北市,
  • Medical Expertise
    1. 消化系統癌症診斷治療、癌症免疫治療及細胞治療、癌症臨床試驗發起及執行
  • License
    腫瘤內科專科醫師、血液病專科醫師、內科專科醫師

[Publications]

PubMed

  1. Shin-Yi Chung*, Yi-Ping Hung*, Yi-Ru Pan, Yu-Chan Chang, Chiao-En Wu, Dennis Shin-Shian Hsu, Peter Mu-Hsin Chang, Meng-Lun Lu, Chi-Ying F Huang, Yeu Su, Michael Hsiao, Chun-Nan Yeh, Ming-Huang Chen. Ruxolitinib Combined with Gemcitabine against Cholangiocarcinoma Growth via the JAK2/STAT1/3/ALDH1A3 Pathway. Biomedicines 2021 Jul 24;9(8):885 (IF 5.61)

  2. Yi-Ping Hung, Yu-Yun Shao, Chiun Hsu, Chih-Hung Hsu, Jan-Mou Lee, Muh-Hwa Yang, Yee Chao. The unique characteristic in peripheral immune cells in patients with advanced hepatocellular carcinoma. Journal of the Formosan Association. 2020. Online 15 December 2020. (IF: 3.282)

  3. Yi-Ping Hung, Yu-Yun Shao, Chiun Hsu, Chih-Hung Hsu, Jan-Mou Lee, Muh-Hwa Yang, Yee Chao. Potential of Circulating Immune Cells as Biomarkers of Nivolumab Treatment Efficacy for Advanced Hepatocellular Carcinoma. J Chin Med Assoc. 2020. 84(2):144-150. (IF: 2.743)

  4. Yi‐Ru Pan, Chiao‐En Wu, Yu‐Chao Wang, Yi‐Chen Yeh, Meng‐Lun Lu, Yi‐Ping Hung, Yee Chao, Da‐Wei Yeh, Chien‐Hsing Lin, Jason Chia‐Hsun Hsieh, Ming‐Huang Chen, Chun‐Nan Yeh. Establishment of a novel gene panel as a biomarker of immune checkpoint inhibitor response. Clin Transl Immunol. 2020, 9: e1145. (IF: 7.271)

  5. Lu L, -C, Hsu C, Shao Y, -Y, Chao Y, Yen C, -J, Shih I-L, Hung Y, -P, Chang C, -J, Shen Y, -C, Guo J, -C, Liu T, -H, Hsu C, -H, Cheng A, -L: Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. Liver Cancer 2019;8:480-490. (IF: 11.740)

  6. Hung YP, Chen MH, Lin JS, Hsiao CF, Shan YS, Chen YC, Chen LT, Liu TW, Li CP, Chao Y. The clinical impact of the novel tumor marker DR-70 in unresectable gastric cancer patients. J Chin Med Assoc. 2018 Jul;81(7):593-598. (IF: 2.743)

  7. Chou WC, Lin PH, Yeh YC, Shyr YM, Fang WL, Wang SE, Liu CY, Chang PM, Chen MH, Hung YP, Li CP, Chao Y, Chen MH. Genes involved in angiogenesis and mTOR pathways are frequently mutated in Asian patients with pancreatic neuroendocrine tumors. Int J Biol Sci. 2016 Nov 25;12(12):1523-1532. (IF: 6.58)

 

回到最上